We reported recently that human and mouse diabetic retina have increased iron accumulation, and inducing
diabetes in a genetic mouse model of systemic iron overload resulted in accelerated progression of diabetic
retinopathy (DR). Iron, although an essential nutrient, when accumulated excessively leads to tissue damage.
However, systemic administration of iron chelators is not a feasible therapeutic option to reduce tissue iron levels
due to potential side effects of lowering serum iron levels. New mechanistic insights into the role of iron in ketone
body synthesis and utilization is a critical gap in knowledge addressed in this application facilitating new
therapeutic targets for DR. During conditions of prolonged fasting and diabetes, body utilizes fatty acids to make
ketone bodies as an alternate metabolic fuel. β- hydroxybutyrate (β-OHB), acetoacetate and acetone, the three
ketones produced in the body, are metabolically important because their accumulation in blood can cause
ketoacidosis and secondly, depending on the physiological state, ketones supply energy for cell survival. The
central hypothesis of this proposal is that retinal iron accumulation during DR inhibits endogenous ketone β-
OHB production, activating NLRP3 inflammasome signaling and thereby accelerating cell death. We will test
our hypothesis using three distinct conceptual, computational and experimental strategies. In aim 1, we will
explore how cellular iron accumulation modulates endogenous ketone body synthesis. Liver, colon and retina
synthesize most of the endogenous ketones. Here, we propose to determine the effect of iron on the function of
the mitochondrial enzyme Bdh1, which catalyzes the final reaction for producing β-OHB, the principal ketone in
circulation using 2 novel mouse lines, constitutive and RPE-specific Bdh1 knockout mice. In aim 2, we will
examine the mechanisms by which iron-associated decrease in ketone body β-OHB impacts inflammation during
DR. Our lab and others have reported that retinal iron increases NLRP3 inflammasome. A report in Nature
Medicine showed that exogenous β-OHB, but not the ketone acetoacetate, reduces NLRP3 inflammasome. Here
we propose to investigate if iron associated reduction in endogenous β-OHB synthesis augments inflammation
through histone deacetylase-Foxo3a signaling. In aim 3, we will explore the effect of iron on the uptake of
hepatic/RPE produced β-OHB by the neuronal cells, which are primarily dependent on ketone bodies during
conditions of low glucose availability. We previously reported that monocarboxylate transporter SMCT1, the only
known β-OHB transporter in ganglion cells, is downregulated during iron overload in retina. We will analyze the
epigenetic mechanisms by which iron alters cellular uptake of β-OHB in neuronal cells causing cell death. The
three proposed aims are supported by the past 10 years of training in iron homeostasis, a vibrant research
environment at SLU, and continuing professional guidance and collaboration with senior faculty. Successful
completion of this project will advance our understanding of how iron alters ketone metabolism and drive the
field into new and underexplored areas, like metabolic reprogramming for efficient ketone body utilization.